

chain nodes :
10 18 19 20 21 22 23 26 29 32 35
 ring nodes :
1 2 3 4 5 6 7 8 9
 ring/chain nodes :
15 16 30 31
 chain bonds :
1-35 4-10 5-15 8-29 18-21 19-20 19-30 20-22 21-23 21-31
 ring bonds :
1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9
 exact/norm bonds :
1-2 1-6 1-35 2-3 2-7 3-4 3-9 4-5 4-10 5-6 5-15 7-8 8-9 8-29 18-21 19-20
19-30 20-22 21-23 21-31
 isolated ring systems :
containing 1 :

G1:C,O,S,N

G2:C,SO2

G3:[*1], [*2], [*3], [*4]

G4:H, [*5]

Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 15:CLASS
 16:CLASS 18:CLASS 19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 26:CLASS 29:CLASS
 30:CLASS 31:CLASS 32:CLASS 35:CLASS

Generic attributes :

26:



Saturation : Unsaturated

Number of Carbon Atoms : less than 7

32:

Saturation : Saturated

Number of Carbon Atoms : less than 7



chain nodes :

10 15 16

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

1-15 4-10 15-16

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

1-2 1-6 1-15 2-3 2-7 3-4 3-9 4-5 4-10 5-6 7-8 8-9 15-16

isolated ring systems :



containing 1 :

G1:C,O,S,N

G2:C,SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 15:CLASS
16:CLASS



chain nodes :

10 15

ring nodes :

1 2 3 4 5 6 7 8 9

chain bonds :

4-10 6-15

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-10 5-6 6-15 7-8 8-9

isolated ring systems :

containing 1 :

G1:C,O,S,N

G2:C,SO2

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 15:CLASS

=>
Uploading 10634225.str

L1 STRUCTURE uploaded

=> d l1
L1 HAS NO ANSWERS
L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 16:23:32 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 586 TO ITERATE

100.0% PROCESSED 586 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 10268 TO 13172
PROJECTED ANSWERS: 1503 TO 2737

L2 50 SEA SSS SAM L1

=> s l1 sss ful
FULL SEARCH INITIATED 16:28:24 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 13078 TO ITERATE


100.0% PROCESSED 13078 ITERATIONS 2657 ANSWERS
SEARCH TIME: 00.00.01

L3 2657 SEA SSS FUL L1

=>
Uploading 10634225sub.str

L4 STRUCTURE uploaded

=> d l4
L4 HAS NO ANSWERS
L4 STR



G1 C,O,S,N

G2 C,SO2

Structure attributes must be viewed using STN Express query preparation.

```
=> s l4 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 16:29:09 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED -      88 TO ITERATE

100.0% PROCESSED      88 ITERATIONS          50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):      ONLINE  **COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET): 1198 TO    2322
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):   1181 TO    2299
```

L5 50 SEA SUB=L3 SSS SAM L4

```
=> s l4 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 16:29:17 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED -  2169 TO ITERATE

100.0% PROCESSED      2169 ITERATIONS        2133 ANSWERS
SEARCH TIME: 00.00.01
```

L6 2133 SEA SUB=L3 SSS FUL L4

```
=>
Uploading 10634225sub2.str
```

L7 STRUCTURE UPLOADED

```
=> d l7 sub=l3 sss sam
L7 HAS NO ANSWERS
```

'SSS SAM ' IS NOT A VALID STRUCTURE FORMAT KEYWORD
Structure Formats
SIA ----- Structure Image, Attributes, and map table if it contains
data. (Default)
SIM ----- Structure IMage.
SAT ----- Structure ATtributes and map table if it contains data.
SCT ----- Structure Connection Table and map table if it contains
data.
SDA ----- All Structure DATA (image, attributes, connection table and
map table if it contains data).
NOS ----- NO Structure data.
ENTER STRUCTURE FORMAT (SIM), NOS:end

=> s 17 sub=l3 sss sam
SAMPLE SUBSET SEARCH INITIATED 16:30:35 FILE 'REGISTRY'
SAMPLE SUBSET SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 12 ANSWERS
SEARCH TIME: 00.00.01

PROJECTIONS (WITHIN SPECIFIED SUBSET):	ONLINE	**COMPLETE**
PROJECTED ITERATIONS (WITHIN SPECIFIED SUBSET):	56 TO	504
PROJECTED ANSWERS (WITHIN SPECIFIED SUBSET):	33 TO	447

L8 12 SEA SUB=L3 SSS SAM L7

=> s 17 sub=l3 sss ful
FULL SUBSET SEARCH INITIATED 16:30:46 FILE 'REGISTRY'
FULL SUBSET SCREEN SEARCH COMPLETED - 420 TO ITERATE

100.0% PROCESSED 420 ITERATIONS 411 ANSWERS
SEARCH TIME: 00.00.01

L9 411 SEA SUB=L3 SSS FUL L7

=> s 13 not 16 not 19
L10 117 L3 NOT L6 NOT L9

=> s 110
L11 44 L10

=> d 111 1-44 bib,ab,hitstr

L11 ANSWER 1 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:376573 CAPLUS
 DN 138:379221
 TI Method for treating or preventing inflammatory diseases
 IN Peterson, Ward M.; Yerxa, Benjamin R.
 PA Inspire Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2


DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003039473	A2	20030515	WO 2002-US35775	20021106
	WO 2003039473	A3	20031023		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 2003125299	A1	20030703	US 2002-290213	20021106
PRAI	US 2001-337828P	P	20011106		
OS	MARPAT	138:379221			
AB	The present invention provides a method of preventing or treating ant-inflammatory disease, including but not limited to, sinusitis, rhinitis, conjunctivitis, asthma, dermatitis, inflammatory bowel disease, inflammatory collagen vascular diseases, glomerulonephritis, inflammatory skin diseases, and sarcoidosis. The method comprises administering to a subject a pharmaceutical formulation comprising a nucleotide receptor agonist, such as nucleoside diphosphate, nucleoside triphosphate, or dinucleoside polyphosphate. Preferred indications of the present invention are perennial allergic rhinitis, seasonal allergic rhinitis, infectious allergic rhinitis, and allergic conjunctivitis.				
IT	479677-55-9 479677-64-0				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(method for treating or preventing inflammatory diseases with nucleoside phosphates)				
RN	479677-55-9	CAPLUS			
CN	Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[hydroxy[[hydroxy[[hydroxy(phosphonoxy)phosphinyl]oxy]phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]-2-(3-nitrophenyl)-, P'''.fwdarw.5'-ester with 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 479677-64-0 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosyl-, 5',5'''-(P,P',P''-trihydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




L11 ANSWER 2 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:282402 CAPLUS
 DN 138:304303
 TI Preparation of triazolo[1,5-d]pyrimidine derivatives as adrenergic .alpha.2C receptor antagonists
 IN Uesaka, Noriaki; Imma, Hironori; Kashima, Hajime; Kurokawa, Masako; Nonaka, Hiromi; Kanda, Tomoyuki; Kuwana, Yoshihisa; Toki, Shinichiro; Shimada, Junichi
 PA Kyowa Hakko Kogyo Co., Ltd., Japan
 SO PCT Int. Appl., 318 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003028732	A1	20030410	WO 2002-JP9911	20020926
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG		
PRAI JP 2001-302375	A	20010928		
OS MARPAT 138:304303		JP 2002-23146	A	20020131
AB An adrenergic .alpha.2C receptor antagonist which contains as an active ingredient a fused-ring pyrimidine deriv. represented by the general formula (I) or a pharmacol. acceptable salt thereof [p = an integer of 1 to 3; R1 = H, each (un)substituted lower alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl; R2 = N(R3)(R4), Q1 [wherein R3, R4 = each (un)substituted lower alkyl, aryl, aralkyl, heterocyclyl or heterocyclyl-lower alkyl or R3 and R4 in cooperation with the adjacent nitrogen atom form an (un)substituted heterocyclic group; -A1-A2- = -Y1-CO-Y2-CH2-, -Y3-CH2-Y4-CO-; wherein Y1, Y2, Y3, Y4 = O, (un)substituted NH]; Q = -N:C(R7)-, N(R12)CO, Q2 [wherein R7 = each (un)substituted OH, NH2, or SH; R12 = H, (un)substituted lower alkyl, aralkyl, or heterocyclylalkyl; n = an integer of 1-3; R13, R14 = groups listed in R1]] is provided. The above antagonist is useful in the treatment for and/or prevention of various diseases attributable to the hyperenergia (hyperactivity) of an adrenergic .alpha.2C receptor such as dyskinesia, in particular L-DOPA-induced dyskinesia, and Parkinson's disease. Thus, 3.81 g 5-(3,4-dimethoxybenzylamino)-8-formyl-2-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine was suspended in 182 mL dichloroethane, treated with 1.71 g 1-phenylpiperazine, stirred at room temp. for 0.5 h, treated with 6.38 g sodium triacetoxoborohydride under ice-cooling, and stirred at room temp. for 2 h to give, after workup and silica gel chromatog., 91% 5-(3,4-dimethoxybenzylamino)-2-(2-furyl)-8-(4-phenylpiperazin-1-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine which (4.03 g) was stirred in 4.03 mL CF ₃ SO ₃ H and 4.95 mL anisole at 50.degree. for 1 h to give, after workup and silica gel chromatog., 79% 5-amino-2-(2-furyl)-8-(4-phenylpiperazin-1-ylmethyl)[1,2,4]triazolo[1,5-c]pyrimidine (II). II and 5-amino-2-(2-furyl)-8-(1,2,3,4-tetrahydroisoquinolin-2-				


ylmethyl)[1,2,4]triaza[1,5-c]pyrimidine in vitro inhibited the binding of [methyl-³H]MK-912 to adrenergic .alpha.2C receptor in human liver-derived HepG2 cells by 80 and 96%, resp. A tablet contg. II and an injection soln. contg. 8-[4-(2,3-dichlorophenyl)piperazin-1-ylmethyl]-5-(3,4-dimethoxybenzylamino)-1-(2-furyl)[1,2,4]triazolo[1,5-c]pyrimidine were formulated.

IT 508240-00-4P 508240-01-5P 508240-02-6P
 508240-03-7P 508240-04-8P 508240-05-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prépn. of triazolo[1,5-d]pyrimidine derivs. as adrenergic .alpha.2C receptor antagonists for treatment and/or prevention of dyskinesia, in particular L-DOPA-induced dyskinesia, and Parkinson's disease)

RN 508240-00-4 CAPPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 2-(2-furanyl)-6-methyl-8-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 508240-01-5 CAPPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 2-(2-furanyl)-6-(2-methoxyethyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 508240-02-6 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(2-fluoroethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 508240-03-7 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(cyclohexylmethyl)-2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)




RN 508240-04-8 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 2-(2-furanyl)-6-(phenylmethyl)-8-[(4-phenyl-1-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 508240-05-9 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 2-(2-furanyl)-8-[(4-phenyl-1-piperazinyl)methyl]-6-(3-phenylpropyl)- (9CI) (CA INDEX NAME)



RE.CNT 9

THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 3 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:23529 CAPLUS
 DN 138:73464
 TI Preparation of nucleotide triphosphates for treating epithelia and retinal tissue diseases
 IN Yerxa, Benjamin R.; Douglass, James G.; Shaver, Sammy Ray; Peterson, Ward M.; Brown, Edward G.; Crean, Christopher S.
 PA USA
 SO U.S. Pat. Appl. Publ., 63 pp., Cont.-in-part of U.S. Pat. Appl. 2002 52,337.

CODEN: USXXCO

DT Patent
LA English

FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003008834	A1	20030109	US 2002-82998	20020227
	US 2002052337	A1	20020502	US 2001-934970	20010821
	WO 2003072067	A2	20030904	WO 2003-US6691	20030227
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
PRAI	US 2000-643138	A2	20000821		
	US 2001-934970	A2	20010821		
	US 2002-82998	A	20020227		
OS	MARPAT 138:73464				
AB	Nucleotide triphosphates I wherein B is nucleobase; X is substituted triphosphate; Y is H, OH, OR; Z is H, OH, OR1; with the proviso that Y and Z are both not H; R1 and R2 are independently residues which are linked directly to the 2' and /or 3' oxygens of the furanose or carbocycle via a carbon atom, were prep'd. for treating epithelia and retinal tissue diseases. These mononucleoside phosphates can be made from a mononucleotide that has been modified by attaching a degrdn. resistant substituent on the terminal phosphate of a polyphosphate mononucleotide. By attaching this degrdn. resistant substituent, the stability from degrdn. matches or exceeds those of certain dinucleotides. The present invention relates to compds. and the methods of using such compds. in the diagnosis, prevention or treatment of epithelial and retinal tissue diseases or conditions of humans and other mammals. Such diseases include: epithelial or retinal tissue disease or condition is selected from the group consisting of vaginal and cervical dryness, chronic bronchitis, chronic obstructive pulmonary disorder, pneumonia, cystic fibrosis, ciliary dyskinesia, sinusitis, lung cancer, otitis media, retinal detachment, retinal edema, dry eye, dry mouth, gastro-esophageal reflux disease(GERD), diarrhea, irritable bowel disease, constipation, glaucoma assocd. with elevated intraocular pressure, retinal degenerative diseases, corneal edema, allergic conjunctivitis, ocular surface inflammation, and allergic rhinitis. Thus, 2',3'-O-methylenebenzyl-.gamma.-(2-naphthalene)ATP was prep'd. for treating epithelia and retinal tissue diseases (no data).				

IT 481051-29-0P 481051-38-1P 481051-39-2P


481051-42-7P

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation);
 BIOL (Biological study); PREP (Preparation)
 (prepn. of nucleotide triphosphates for treating epithelia and retinal
 tissue diseases)

RN 481051-29-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-deoxy-5-O-(1,3-dihydroxy-1,3-dioxido-2,4-dioxa-1,3-diphosphhept-1-yl)-3-O-[(phenylamino)carbonyl]-.beta.-D-erythro-pentofuranosyl]-2-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 481051-38-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(3-methylphenyl)-6-[2,3-O-(2-phenylethylidene)-5-O-(1,3,5,7-tetrahydroxy-1,3,5,7-tetraoxido-2,4,6,8-tetraoxa-1,3,5,7-tetraphosphheptadec-1-yl)-.beta.-D-ribosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 481051-39-2 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(3-methoxyphenyl)-6-[5-O-[1,3,5-trihydroxy-7-(2-naphthalenyl)-1,3,5-trioxa-2,4,6-trioxa-1,3,5-triphosphhept-1-yl]-.beta.-D-ribosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 481051-42-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[1,3,5,7-tetrahydroxy-8-(1-naphthalenyl)-1,3,5,7-tetraoxido-2,4,6-trioxa-1,3,5,7-tetrephosphaoct-1-yl]-.beta.-D-ribofuranosyl]-2-[3-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 4 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:5682 CAPLUS
 DN 138:78562
 TI Joint lubrication with P2Y purinergic receptor agonists
 IN Cowlen, Matthew S.; Yerxa, Benjamin R.; Jones, Arthur C.; Brown, Edward G.
 PA Inspire Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 33 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003000056	A1	20030103	WO 2002-US20703	20020625
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2003027785	A1	20030206	US 2002-183320	20020625
PRAI	US 2001-300942P	P	20010625		
OS	MARPAT 138:78562				
AB	The present invention is directed to a method of altering the amt. or compn. of synovial fluids secreted from joints in a subject in need of such treatment. The method comprises administering to a subject a pharmaceutical compn. comprising a P2Y purinergic receptor agonist in an amt. effective to alter the amt. or compn. of synovial fluids. The P2Y purinergic receptor agonist is administered in an amt. effective to stimulate secretion of synovial fluid, lubricin, hyaluronic acid, or surface-active phospholipids; to enhance joint lubrication; or to treat osteoarthritis. The pharmaceutical compns. useful in the present invention comprise a P2Y purinergic receptor agonists include, but are not limited to: uridine-, adenosine-, cytidine-5'-di- or triphosphates, dinucleoside polyphosphates, and analogs thereof. The invention is useful for treating conditions assocd. with reduced joint lubrication and joint stiffness, such as osteoarthritis.				
IT	479677-55-9 479677-64-0				
	RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (joint lubrication with P2Y purinergic receptor agonists)				
RN	479677-55-9 CAPLUS				
CN	Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[hydroxy[[hydroxy[[hydroxy(phosphonoxy)phosphinyl]oxy]phosphinyl]oxy]phosphinyl]-.beta.-D-ribofuranosyl]-2-(3-nitrophenyl)-, P'''.fwdarw.5'-ester with 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 479677-64-0 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosyl-, 5',5'''-(P,P',P''-trihydrogen triphosphate) (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 5 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:965116 CAPLUS
 DN 138:33376
 TI Method of treating dry eye disease with purinergic receptor agonists
 IN Yerxa, Benjamin R.; Jacobus, Karla; Pendergast, William; Rideout, Janet L.
 PA USA
 SO U.S. Pat. Appl. Publ., 18 pp., Cont.-in-part of U.S. Ser. No. 171,169.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193340	A1	20021219	US 2001-27520	20011219
	US 5900407	A	19990504	US 1997-797472	19970206
	WO 9834593	A1	19980813	WO 1998-US2701	19980206
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
PRAI	US 1997-797472	W	19970206		
	WO 1998-US2701	W	19980206		
	US 1998-171169	A2	19981014		
OS	MARPAT	138:33376			
AB	This invention is directed to a method of stimulating tear secretion and mucin prodn. in eyes. The method comprises the step of administering to the eyes of a subject a compn. comprising a dinucleotide of Formula I (X = oxygen, imido, methylene or difluoromethylene; Y = H or OH; Y' = H or OH; n = 0, 1, or 2; m = 0, 1, or 2; n+m = 0-4; B and B' are each independently a purine such as adenine; RX = O, H or is absent; RY = hydrogen, chlorine, amino, monosubstituted amino, disubstituted amino, alkylthio, arylthio, or aralkylthio, wherein the substituent on the sulfur contains up to 20 carbon atoms; RZ is oxo, mercapto, thione, alkylthio, arylthio, aralkylthio, acylthio, alkyloxy, etc.; R3 is hydrogen, azido, alkoxy, aryloxy, aralkyloxy, alkylthio, arylthio, aralkylthio, amino, monosubstituted amino, disubstituted amino, etc.) its pharmaceutically acceptable salts, in an amt. effective to stimulate tear fluid secretion. The method of the present invention may be used to increase tear prodn. for any reason, including, but not limited to, treatment of dry eye disease and corneal injury. Pharmaceutical formulations and methods of making the same are also disclosed. Methods of administering the same would include: topical administration via a liq., gel, cream, or as part of a contact lens or selective release membrane; or systemic administration via nasal drops or spray, inhalation by nebulizer or other device, oral form (liq. or pill), injectable, intra-operative instillation or suppository form.				
IT	401618-87-9				
	RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
	(method of treating dry eye disease with purinergic receptor agonists such as dinucleotides)				
RN	401618-87-9	CAPLUS			
CN	Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with 2-(4-bromophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-				


one (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A




PAGE 1-B



L11 ANSWER 6 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:373581 CAPLUS
 DN 137:200995
 TI The first reliable, general synthesis of the 5-oxo derivatives of 5,6-dihydro-1,2,4-triazolo[4,3-c]pyrimidine and the rates of isomerization of the [4,3-c] compounds into their [1,5-c] isomers
 AU Nagamatsu, Tomohisa; Fujita, Takayuki
 CS Faculty of Pharmaceutical Sciences, Okayama University, Okayama, Japan
 SO Heterocycles (2002), 57(4), 631-636
 CODEN: HTCYAM; ISSN: 0385-5414
 PB Japan Institute of Heterocyclic Chemistry
 DT Journal
 LA English
 OS CASREACT 137:200995
 AB This paper describes a reliable synthesis of the 5-oxo derivs. (8, VIII; R1-R3 = H, Me; R4 = H, Me, Ph) of 5,6-dihydro-1,2,4-triazolo[4,3-c]pyrimidine, by the reaction of 2-oxo-1,2-dihydropyrimidin-4-ylhydrazines with the appropriate tri-Et orthoesters in trifluoroacetic acid below 30 .degree.C or by the oxidative cyclization of their aldehyde hydrazones with 70% nitric acid in trifluoroacetic acid below 40 .degree.C, and the rates of isomerization of the [4,3-c] compds. (8) into the [1,5-c] isomers (9, IX).
 IT **452324-04-8P 452324-06-0P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (the first reliable, general synthesis of the 5-oxo derivs. of 5,6-dihydro-1,2,4-triazolo[4,3-c]pyrimidine and the rates of isomerization of the [4,3-c] compds. into their [1,5-c] isomers)
 RN 452324-04-8 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 2,6-dimethyl- (9CI) (CA INDEX NAME)



RN 452324-06-0 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 7 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:332678 CAPLUS
 DN 136:350561
 TI Use of P2Y12 receptor antagonists as platelet aggregation inhibitors
 IN Boyer, Jose L.; Olins, Gillian M.; Yerxa, Benjamin R.; Douglass, James G.
 PA USA
 SO U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U. S. Ser. No. 643,138.
 CODEN: USXXCO

DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002052337	A1	20020502	US 2001-934970	20010821
	US 2002128224	A1	20020912	US 2002-87551	20020227
	US 2003008834	A1	20030109	US 2002-82998	20020227
PRAI	US 2000-643138	A2	20000821		
	US 2001-934970	A2	20010821		

OS MARPAT 136:350561

AB The invention discloses a method of preventing or treating diseases or conditions assocd. with platelet aggregation and treating thrombosis. The method involves administering to a subject a pharmaceutical compn. comprising a therapeutic effective amt. of P2Y12 receptor antagonist compd., to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compds. disclosed include mononucleoside polyphosphates and dinucleoside polyphosphates.

IT 401618-87-9P 401618-93-7P 401618-99-3P

401619-05-4P


RL: SPN (Synthetic preparation); PREP (Preparation)
 (P2Y12 receptor antagonists as platelet aggregation inhibitors)

RN 401618-87-9 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with
 2-(4-bromophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-
 one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401618-93-7 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with
2-(4-bromophenyl)-6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)imidazo[1,2-c]pyrimidin-5(6H)-one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401618-99-3 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-bromophenyl)-6-.beta.-D-
ribofuranosyl-, 5',5'''-(P,P',P'',P''')-tetrahydrogen tetraphosphate) (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401619-05-4 CAPLUS


CN Cytidine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with
2-[1,1'-biphenyl]-4-yl-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-
5(6H)-one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 8 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:157789 CAPLUS
 DN 136:200422
 TI Preparation of nucleotides as P2Y12 receptor antagonists and as inhibitors of ADP-induced platelet aggregation
 IN Boyer, Jose L.; Olins, Gillian M.; Yerxa, Benjamin R.; Douglass, James G.
 PA Inspire Pharmaceuticals, Inc., USA; University of North Carolina
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002016381	A2	20020228	WO 2001-US41818	20010820
	WO 2002016381	A3	20020510		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001085470	A5	20020304	AU 2001-85470	20010820
	EP 1311525	A2	20030521	EP 2001-964633	20010820
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRAI	US 2000-643138	A	20000821		
	WO 2001-US41818	W	20010820		
OS	MARPAT	136:200422			
AB	This invention is directed to a method of preventing or treating diseases or conditions assocd. with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical compn. comprising a therapeutic effective amt. of P2Y12 receptor antagonist compd., wherein said amt. is effective to bind the P2Y12 receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12 receptor antagonist compds. useful for this invention include mononucleoside polyphosphates I wherein Q is [X1-P(=T1)(OM)]p; L is [P(=T2)(OM)-X3]m; X1-X3 are independently oxygen, methylene, monochloromethylene, dichloromethylene, monofluoromethylene, difluoromethylene, or imido; T1, T2, W, and V are independently oxygen or sulfur; m = 0, 1 or 2; n = 0 or 1; p = 0, 1, or 2; where the sum of m + n + p is from 1 to 5; M = H or a pharmaceutically-acceptable inorg. or org. counterion; A = M; B is nucleobase; D = O or C; Y = H, OH, or OR1; Z = H, OH, or OR2; with the proviso that at least one of Y and Z is OR1 or OR2; R1 and R2 are residues which are linked directly to the 2' and /or 3'-hydroxy of the furanose or carbocycle or linked directly to two of the 2' and 3'-hydroxyls of the furanose or carbocycle via a common carbon atom. The present invention also provides novel compns. comprising mononucleoside polyphosphates and dinucleoside polyphosphates. Thus, p1-[(4-phenylphenyl)ethenocytidine 5'-]-P4-(cytidine 5') tetraphosphate was prep'd. and tested on human blood platelets and in rats as P2Y12 receptor antagonists and as inhibitors of ADP-induced platelet aggregation.				
IT	401618-87-9P	401618-93-7P	401618-99-3P		
	401619-05-4P				


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of nucleotides as P2Y12 receptor antagonists and as inhibitors of ADP-induced platelet aggregation)

RN 401618-87-9 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with 2-(4-bromophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401618-93-7 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with 2-(4-bromophenyl)-6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)imidazo[1,2-c]pyrimidin-5(6H)-one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401618-99-3 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-bromophenyl)-6-.beta.-D-
ribofuranosyl-, 5',5'''-(P,P',P'',P''')-tetrahydrogen tetraphosphate) (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 401619-05-4 CAPLUS


CN Cytidine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with
2-[1,1'-biphenyl]-4-yl-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-
5(6H)-one (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L11 ANSWER 9 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:136070 CAPLUS
 DN 136:151393

TI Preparation of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency

IN Pendergast, William; Yerxa, Benjamin R.; Rideout, Janet L.; Siddiqi, Suhaib M.

PA Inspire Pharmaceuticals, Inc., USA

SO U.S., 15 pp., Cont.-in-part of U.S. 5,900,407.
 CODEN: USXXAM

DT Patent

LA English

FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6348589	B1	20020219	US 1998-101395	19980710
	US 5900407	A	19990504	US 1997-797472	19970206
	US 5837861	A	19981117	US 1997-798508	19970210
	WO 9834942	A2	19980813	WO 1998-US2702	19980206
	WO 9834942	A3	20000106		
		W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
		RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG		
	US 2002082417	A1	20020627	US 2001-7451	20011106
	US 2003186917	A1	20031002	US 2003-397795	20030325
PRAI	US 1997-797472	A2	19970206		
	US 1997-798508	A2	19970210		
	WO 1998-US2702	W	19980206		
	US 1998-101395	A1	19980710		
	US 2001-774752	A2	20010130		
OS	MARPAT 136:151393				
AB	The present invention relates to certain novel dinucleotides I (X = O, CH ₂ , imido, CF ₂ ; B, B1 = independently nucleobase; Z, Z1 = independently OH, N ₃ ; Y, Y1 = independently H, OH; Q = (HPO ₃) _m ; n = 0-2; m = 0-2; n + m = 0-4) and formulations thereof which are highly selective agonists of the P2Y2 and/or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compds. of the present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and retinal detachment. Thus, P ₁ ,P ₂ -di(uridine-5'-)-P ₂ ,P ₃ -methylenetetraphosphate was prep'd. as P2Y2 and/or P2Y4 purinergic receptor (EC ₅₀ = 11.1 .mu.mol).				

IT **211448-72-5P**

RL: BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency)


RN 211448-72-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[hydroxy[[hydroxy[[hydroxy(phosp

honoxy)phosphinyl]oxy]phosphinyl]oxy]phosphinyl]-.beta.-D-ribofuranosyl]-2-(3-nitrophenyl)-, P'''.fdarw.5'-ester with 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one, tetraammonium salt (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● 4 NH₃

PAGE 1-B



RE.CNT 93 THERE ARE 93 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 10 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:763523 CAPLUS
 DN 135:298823
 TI Use of P2Y receptor agonist dinucleotide compounds to stimulate removal of fluid in retinal detachment and retinal edema
 IN Peterson, Ward M.; Yerxa, Benjamin R.
 PA Peterson, Ward M., USA
 SO U.S. Pat. Appl. Publ., 20 pp., Cont.-in-part of U.S. 5,837,861.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2001031743	A1	20011018	US 2001-774752	20010130
	US 6596725	B2	20030722		
	US 5837861	A	19981117	US 1997-798508	19970210
	ZA 9801073	A	19990219	ZA 1998-1073	19980210
	US 2002103158	A1	20020801	US 2001-817017	20010323
	US 6555675	B2	20030429		
	WO 2002060454	A2	20020808	WO 2002-US3934	20020129
	WO 2002060454	A3	20021227		
	WO 2002060454	B1	20030213		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	EP 1355652	A2	20031029	EP 2002-714865	20020129
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2003186917	A1	20031002	US 2003-397795	20030325
PRAI	US 1997-798508	A2	19970210		
	WO 1998-US2702	W	19980206		
	US 1998-101395	A2	19980710		
	US 2001-774752	A2	20010130		
	US 2001-817017	A	20010323		
	WO 2002-US3934	W	20020129		
OS	MARPAT	135:298823			
AB	The invention provides a method of treating edematous retinal disorders. The method comprises administration of a P2Y receptor agonist to stimulate the removal of pathol. extraneous fluid from the subretinal and retinal spaces and thereby reduce the accumulation of said fluid assocd. with retinal detachment and retinal edema. The P2Y receptor agonist may be administered with therapeutic and adjuvant agents commonly used to treat edematous retinal disorders. The pharmaceutical compn. useful in this invention comprises a P2Y receptor agonist with enhanced resistance to extracellular hydrolysis, such as dinucleoside polyphosphate compds.				
IT	211448-72-5 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (P2Y receptor agonist dinucleotide compds. to stimulate removal of				

fluid in retinal detachment and retinal edema)
 RN 211448-72-5 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[hydroxy[[hydroxy[[hydroxy(phosphonoxy)phosphinyl]oxy]phosphinyl]oxy]phosphinyl]-beta-D-ribofuranosyl]-2-(3-nitrophenyl)-, P'''.fwdarw.5'-ester with 2-(3-nitrophenyl)-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one, tetraammonium salt (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



● 4 NH₃

PAGE 1-B



L11 ANSWER 12 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2000:457085 CAPLUS
 DN 133:85091
 TI Targeted gene transfer and internalization of virus vectors using G protein coupled receptors
 IN Boucher, Richard C., Jr.; Pickles, Raymond J.; Rideout, Janet L.;
 Pendergast, William; Yerxa, Benjamin R.; Douglass, James G., III
 PA The University of North Carolina At Chapel Hill, USA
 SO PCT Int. Appl., 86 pp.
 CODEN: PIXXD2


DT Patent
 LA English
 FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000039145	A1	20000706	WO 1999-US30658	19991222
	W: AE, AL, AM, AT, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, CZ, DE, DE, DK, DK, EE, EE, ES, FI, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1140967	A1	20011010	EP 1999-966577	19991222
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRAI	US 1998-219672	A	19981223		
	US 1998-219698	A	19981223		
	WO 1999-US30658	W	19991222		
OS	MARPAT	133:85091			
AB	A method of delivering foreign nucleic acid (e.g., a gene) into a cell by attaching a virus contg. the nucleic acid to a G protein coupled receptor (i.e., a seven transmembrane receptor such as the P2Y2 receptor) that is internalized upon ligand binding. The virus may be attached to the receptor by means of a bridging antibody, or by binding an antibody specific for the receptor with an antibody specific for the virus, wherein the antibody that specifically binds with the receptor and the antibody that specifically binds to the virus are cross-linked. Alternatively, the virus may express a peptide that specifically binds to the receptor. The receptor may be induced to internalize by means of the addn. of a ligand known to trigger internalization of the receptor into the cell. Purinoceptors, specifically the P2Y2 receptor, were identified on the surface of the apical surface of the airway epithelium. Cells presenting the P2Y2 receptor contg. a hemagglutinin epitope were incubated with adenovirus carrying a lacZ reporter gene and labeled with a bispecific antibody to the epitope and the knob protein of adenovirus. The virus was rapidly internalized upon exposing the cells to ATP.gamma.S.				
IT	280549-89-5P RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (prepn. and reactions of; targeted gene transfer and internalization of virus vectors using G protein coupled receptors)				
RN	280549-89-5 CAPLUS				
CN	Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with 6-bromo-N-[4-[6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-5,6-dihydro-5-oxoimidazo[1,2-c]pyrimidin-2-yl]phenyl]hexanamide, tetraammonium salt				


(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

● 4 NH₃

PAGE 1-B



IT 280549-91-9P 280549-92-0P

RL: BUU (Biological use, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. and uses of; targeted gene transfer and internalization of virus vectors using G protein coupled receptors)

RN 280549-91-9 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with 6-amino-N-[4-[6-(2-deoxy-.beta.-D-erythro-pentofuranoyl)-5,6-dihydro-5-oxoimidazo[1,2-c]pyrimidin-2-yl]phenyl]hexanamide, tetraammonium salt
(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A

● 4 NH₃

PAGE 1-B




RN 280549-92-0 CAPLUS


CN Uridine 5'-(pentahydrogen tetraphosphate), P'''.fwdarw.5'-ester with (3aS,4S)-N-[6-[[6-[[4-[6-[(2-deoxy-.beta.-D-erythro-pentofuranoyl)-5,6-dihydro-5-oxoimidazo[1,2-c]pyrimidin-2-yl]phenyl]amino]-6-oxohexyl]amino]-6-oxohexyl]hexahydro-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide, tetraammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A

● 4 NH₃

PAGE 1-B



PAGE 1-C





RE.CNT 7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 14 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1999:303372 CAPLUS
 DN 131:59079
 TI A Dimroth rearrangement of pyrimidine nucleosides
 AU Loakes, David; Brown, Daniel M.; Salisbury, Stephen A.
 CS Laboratory of Molecular Biology, Medical Research Council, Cambridge, CB2
 2QH, UK
 SO Journal of the Chemical Society, Perkin Transactions 1: Organic and
 Bio-Organic Chemistry (1999), (10), 1333-1338
 CODEN: JCPRB4; ISSN: 0300-922X
 PB Royal Society of Chemistry
 DT Journal
 LA English
 OS CASREACT 131:59079
 AB N4-Acylamino-2'-deoxycytidine derivs. undergo acid-promoted cyclization to give [1,2,4]triazolo[4,3-c]pyrimidin-5(6H)-ones in the presence of pyridinium chloride. This reaction has been demonstrated for a series of analogs. Treatment of the cyclized products in basic media gives rise to a novel Dimroth-type rearrangement leading to [1,2,4]triazolo[1,5-c]pyrimidin-5(6H)-ones. The crystal structure of one such product was confirmed by X-ray anal.
 IT 228406-30-2P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (Dimroth rearrangement of pyrimidine nucleosides)
 RN 228406-30-2 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 8-(2-chloroethyl)-6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 209159-60-4P 228406-24-4P 228406-40-4P
 228406-41-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (Dimroth rearrangement of pyrimidine nucleosides)
 RN 209159-60-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(3,5-di-O-acetyl-2-deoxy-.beta.-D-erythro-pentofuranosyl)-2,8-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228406-24-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-2,8-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228406-40-4 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-8-methyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 228406-41-5 CAPLUS

CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-8-methyl-2-(phenoxy)methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 15 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:550430 CAPLUS
 DN 129:175919
 TI Preparation of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency
 IN Pendergast, William; Yerxa, Benjamin R.; Rideout, Janet L.; Siddiqi, Suhaib M.
 PA Inspire Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 49 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 14

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9834942	A2	19980813	WO 1998-US2702	19980206
	WO 9834942	A3	20000106		
	W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
	US 5900407	A	19990504	US 1997-797472	19970206
	US 5837861	A	19981117	US 1997-798508	19970210
	AU 9863242	A1	19980826	AU 1998-63242	19980206
	AU 738907	B2	20010927		
	EP 981534	A2	20000301	EP 1998-907435	19980206
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	BR 9807169	A	20000606	BR 1998-7169	19980206
	JP 2001526635	T2	20011218	JP 1998-535055	19980206
	NZ 337225	A	20020328	NZ 1998-337225	19980206
	US 6348589	B1	20020219	US 1998-101395	19980710
	NO 9903776	A	19991006	NO 1999-3776	19990804
	US 2002082417	A1	20020627	US 2001-7451	20011106
	US 2003036527	A1	20030220	US 2002-163804	20020605
	US 6673779	B2	20040106		
	US 2003186917	A1	20031002	US 2003-397795	20030325
PRAI	US 1997-797472	A2	19970206		
	US 1997-798508	A2	19970210		
	WO 1998-US2702	W	19980206		
	US 1998-101395	A1	19980710		
	US 1998-101840	A2	19980717		
	US 2001-774752	A2	20010130		
	US 2001-7451	A2	20011106		

OS MARPAT 129:175919

AB The present invention relates to certain novel dinucleotides I ($X = O$, CH_2 , imido, CF_2 ; B , $B1$ = independently nucleobase; Z , $Z1$ = independently OH , $N3$; Y , $Y1$ = independently H , OH ; $Q = (HPO_3)^m$; $n = 0-2$; $m = 0-2$; $n + m = 0-4$) and formulations thereof which are highly selective agonists of the P2Y2 and/or P2Y4 purinergic receptor. They are useful in the treatment of chronic obstructive pulmonary diseases such as chronic bronchitis, PCD, cystic fibrosis, as well as prevention of pneumonia due to immobility. Furthermore, because of their general ability to clear retained mucus secretions and stimulate ciliary beat frequency, the compds. of the

present invention are also useful in the treatment of sinusitis, otitis media and nasolacrimal duct obstruction. They are also useful for treatment of dry eye disease and retinal detachment. Thus, P1,P2-di(uridine-5')-P2,P3-methylenetetraphosphate was prep'd. as P2Y2 and/or P2Y4 purinergic receptor (EC50 = 11.1 .mu.mol).

IT

211448-72-5P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of dinucleotides and their use as modulators of mucociliary clearance and ciliary beat frequency)

RN


211448-72-5 CAPLUS


CN

Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[5-O-[hydroxy[[hydroxy[[hydroxy(phosphonoxy)phosphinyl]oxy]phosphinyl]oxy]phosphinyl]-.beta.-D-ribofuranosyl]-2-(3-nitrophenyl)-, P'''.fwdarw.5'-ester with 2-(3-nitrophenyl)-6-.beta.a.-D-ribofuranosylimidazo[1,2-c]pyrimidin-5(6H)-one, tetraammonium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A

●4 NH₃



L11 ANSWER 16 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:332717 CAPLUS
 DN 129:81907
 TI Cyclization and rearrangement of N4-acylaminodeoxycytidines
 AU Loakes, David; Brown, Daniel M.; Salisbury, Stephen A.
 CS Medical Res. Council, Center Protein Engineering, Cambridge, CB2 2QH, UK
 SO Tetrahedron Letters (1998), 39(22), 3865-3868
 CODEN: TELEAY; ISSN: 0040-4039
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB N4-Acetylaminoo-2'-deoxycytidine undergoes an acid promoted cyclization to give a 1,2,4-triazolo[4,3-c]pyrimidinone which, under basic conditions, isomerizes via a Dimroth-type rearrangement to the 1,2,4-triazole[1,5-c]pyrimidinone.
 IT **209159-60-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cyclization and rearrangement of N-acylaminodeoxycytidines)
 RN 209159-60-4 CAPLUS
 CN [1,2,4]Triazolo[1,5-c]pyrimidin-5(6H)-one, 6-(3,5-di-O-acetyl-2-deoxy-.beta.-D-erythro-pentofuranosyl)-2,8-dimethyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 17 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:757803 CAPLUS
 DN 128:84026
 TI Structure-activity relationship of pyrimidine heterosubstituted nucleoside analogs
 AU Mansour, Tarek S.; Evans, Colleen A.; Siddiqui, M. Arshad; Charron, Marie;
 Zacharie, Boulos; Nguyen-Ba, Nghe; Lee, Nola; Korba, Brent
 CS BioChem Therapeutic Inc., Laval, QC, H7V 4A7, Can.
 SO Nucleosides & Nucleotides (1997), 16(7-9), 993-1001
 CODEN: NUNUD5; ISSN: 0732-8311
 PB Marcel Dekker, Inc.
 DT Journal
 LA English
 AB The structure-activity relation of sixteen 3-deaza, C-4 substituted pyrimidines and imidazo[1,2-c]pyrimidine bases of 1,3-oxathiolanes and 1,3-dioxolanes revealed good anti-HBV activity in 2.2.15 cells transfected with human hepatitis B virus of the imidazo[1,2-c]pyrimidine nucleosides. Two procedures for the prepn. of C-4 substituted analogs are reported based on nucleophilic displacement of a sulfonamide or imidazole by a variety of nitrogen nucleophiles.
 IT 188251-77-6P 188251-78-7P 188251-80-1P
 188251-82-3P 188251-83-4P 188251-96-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. and anti-hepatitis B virus structure-activity relationship of pyrimidine heterosubstituted nucleoside analogs)
 RN 188251-77-6 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(4-nitrophenyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188251-78-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 5,6-dihydro-6-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-5-oxo-, ethyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-80-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 188251-82-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-83-4 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-96-9 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 188251-79-8P 188251-84-5P 188251-87-8P

188251-98-1P 188251-99-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and anti-hepatitis B virus structure-activity relationship of pyrimidine heterosubstituted nucleoside analogs)

RN 188251-79-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-84-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-(4-nitrophenyl)-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-87-8 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-5,6-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-98-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyloxy)methyl]-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)-, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-99-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyloxy)methyl]-1,3-dioxolan-4-yl]-2-(4-fluorophenyl)-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 18 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:437580 CAPLUS
 DN 127:109143
 TI Synthesis of some 4,5-cyclo cytosine nucleosides
 AU Ahmed, A. F. Sayed
 CS Fac. Sci., Zagazig Univ., Zagazig, Egypt
 SO Bulletin of the Polish Academy of Sciences, Chemistry (1997), Volume Date
 1996, 44(4), 209-213
 CODEN: BPACEQ; ISSN: 0239-7285
 PB Polish Academy of Sciences
 DT Journal
 LA English
 AB Synthesis of some 4,5-cyclo cytosine nucleoside derivs. was performed by the individual reactions of 5-hydroxy, 5-mercaptop and 5-amino cytidines with chloroethyl formate, thionyl chloride and thiophosgene, successively. On the other hand, reactions of cytidine with chloroacetone or chloropropionaldehyde produced 3,4-cyclized cytidine products.
 IT 188532-28-7P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of some cyclo cytosine nucleosides)
 RN 188532-28-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 19 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:211716 CAPLUS
 DN 126:251347
 TI Synthesis of some cytidine derivatives
 AU Sayed ahmed, A. F.; El-Kafrawi, E.
 CS Faculty of Science, Zagazig University, Zagazig, Egypt
 SO Egyptian Journal of Pharmaceutical Sciences (1996), 37(1-6), 501-507
 CODEN: EJPSBZ; ISSN: 0301-5068
 PB National Information and Documentation Centre
 DT Journal
 LA English
 AB Synthesis of some cytidine derivs. involving 4,5-cyclization are performed by the individual reactions of both of 5-hydroxy, 5-mercaptop, and 5-amino cytidines with chloroethyl formate, thionyl chloride, and thiophosgene successively. On the other hand, reactions of cytidine with chloroacetone or chloropropionaldehyde give 3,4-cyclized cytidine products.
 IT **188532-28-7P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (cyclocondensation of cytidine with chloroethyl formate, thionyl chloride, and thiophosgene)
 RN 188532-28-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-[2,3-O-(1-methylethylidene)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 20 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1997:119490 CAPLUS
 DN 126:225501
 TI Discovery of imidazo[1,2-c]pyrimidin-5(6H)-one heterosubstituted nucleoside analogs with potent activity against human hepatitis B virus in vitro
 AU Mansour, Tarek S.; Evans, Colleen A.; Charron, Marie; Korba, Brent E.
 CS BioChem Therapeutic Inc., Laval, QC, H7V 4A7, Can.
 SO Bioorganic & Medicinal Chemistry Letters (1997), 7(3), 303-308
 CODEN: BMCLE8; ISSN: 0960-894X
 PB Elsevier
 DT Journal
 LA English
 AB Eleven novel imidazo[1,2-c]pyrimidin-5(6H)-one dideoxynucleoside analogs in which the sugar ring is 1,3-dioxolane or 1,3-oxathiolane were synthesized and their in vitro antihepatitis B virus (HBV) activities were compared in the chronically HBV-producing human cell line 2.2.15. Seven nucleoside analogs (including I, which possesses trans relative stereochem.) displayed good potency and selectivity towards HBV. None of the tested imidazo[1,2-c]pyrimidines inhibited the replication of HIV-1 in MT-4 cells.
 IT **188251-77-6P 188251-78-7P 188251-80-1P**
188251-82-3P 188251-83-4P 188251-85-6P
188251-96-9P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of imidazopyrimidinone heterosubstituted nucleoside analogs with potent activity against human hepatitis B virus in vitro)
 RN 188251-77-6 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(4-nitrophenyl)-, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 188251-78-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 5,6-dihydro-6-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-5-oxo-, ethyl ester, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-80-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 188251-82-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-83-4 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-85-6 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[{(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-96-9 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 188251-79-8P 188251-84-5P 188251-87-8P

188251-94-7P 188251-95-8P 188251-98-1P

188251-99-2P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of imidazopyrimidinone heterosubstituted nucleoside analogs with potent activity against human hepatitis B virus in vitro)

RN 188251-79-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[{(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl}-1,3-oxathiolan-5-yl]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-84-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-(4-nitrophenyl)-, (2S-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-87-8 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-5,6-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-94-7 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[2-[(benzoyloxy)methyl]-1,3-dioxolan-4-yl]-5,6-dihydro-5-oxo-, propyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-95-8 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-dioxolan-4-yl]-5,6-dihydro-5-oxo-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-98-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)-, (2R-cis)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-99-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[2-[[[(1,1-dimethylethyl)dimethylsilyloxy]methyl]-1,3-dioxolan-4-yl]-2-(4-fluorophenyl)-, (2R-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 188251-97-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of imidazopyrimidinone heterosubstituted nucleoside analogs
with potent activity against human hepatitis B virus in vitro)

RN 188251-97-0 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[2-(hydroxymethyl)-1,3-dioxolan-4-yl]-, (2S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 21 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:534075 CAPLUS
 DN 111:134075
 TI Synthesis of (imidazo[1,2-c]pyrimidin-2-yl)phenylmethanones and
 6-benzoylpyrrolo[2,3-d]pyrimidinones
 AU Danswan, Geoffrey; Kennewell, Peter D.; Tully, W. Roger
 CS Roussel Lab. Ltd., Wiltshire, SN3 5BZ, UK
 SO Journal of Heterocyclic Chemistry (1989), 26(2), 293-9
 CODEN: JHTCAD; ISSN: 0022-152X
 DT Journal
 LA English
 OS CASREACT 111:134075
 AB 4-Pyrimidinamines have been reacted with 3-bromo-1-phenylpropane-1,2-dione
 to give a series of (imidazopyrimidinyl)phenylmethanones I (R1 = MeO, MeS;
 R2 = Me, Et, MeS, MeO, EtO, H, Pr, CH₂:CHCH₂). The dione also reacted
 with Et amidinoacetate to yield Et 2-amino-5-benzoylpyrrole-2-carboxylate
 which was used to prep. a series of benzoylpyrrolopyrimidines II (R3 = H,
 Me, null; R4 = O, S, MeO, MeS; R5 = H, Me).
 IT 98567-04-5P 98567-05-6P 98567-09-0P
 98567-11-4P 98567-16-9P 98567-17-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 98567-04-5 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-methoxy- (9CI) (CA
 INDEX NAME)




RN 98567-05-6 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-propyl- (9CI)
 (CA INDEX NAME)




RN 98567-09-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-methyl- (9CI)
 (CA INDEX NAME)




RN 98567-11-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-(2-propenyl)-
 (9CI) (CA INDEX NAME)



RN 98567-16-9 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-(methylthio)- (9CI)
 (CA INDEX NAME)



RN 98567-17-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-(methylthio)-6-(2-propenyl)-
 (9CI) (CA INDEX NAME)



L11 ANSWER 22 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1989:439383 CAPLUS

DN 111:39383

TI 2-Aroylimidazo[1,2-c]pyrimidine derivatives as anxiolytics, their preparation, and formulations containing them

PA Roussel-UCLAF, Fr.

SO Israeli, 25 pp.

CODEN: ISXXAQ

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	IL 73809	A1	19880331	IL 1984-73809	19841212
PRAI	IL 1984-73809		19841212		
OS	MARPAT 111:39383				
AB	The title compds. I (R = Ph; R1 = H, C1-5 alkyl, alkoxy, alkylthio; R2R3 = bond, or R1R2 = O and R3 = H, C1-5 alkyl, C2-5 alkenyl; R4 = C1-5 alkoxy, alkylthio; R5 = H, C1-5 alkyl), useful as anxiolytics, were prep'd. A mixt. of 2,6-dimethoxy-4-pyrimidinamine and 3-bromo-1-phenyl-1,2-propanedione in Et ₂ O was stirred overnight. The resulting cryst. salt was collected and dissolved in EtOH, and the soln. was refluxed for 2 h to give the corresponding imidazopyrimidinone deriv., which was ethylated to give 2-benzoyl-6-ethyl-7-methoxyimidazo[1,2-c]pyrimidin-5(6H)-one (II). In the Geller and Seifter test for anxiolytic activity, II in vivo exhibited a min. ED of 2 mg/kg p.o. (test species unspecified). Tablets contg. II 20 mg and other ingredients (lactose, starch, talc, and Mg stearate) q.s. to 150 mg were prep'd.				


IT 98567-04-5P 98567-05-6P 98567-09-0P

98567-11-4P 98567-16-9P 98567-17-0P

RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of, as anxiolytic)


RN 98567-04-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-methoxy- (9CI) (CA INDEX NAME)




RN 98567-05-6 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-propyl- (9CI)
 (CA INDEX NAME)




RN 98567-09-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-methyl- (9CI)
 (CA INDEX NAME)



RN 98567-11-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 98567-16-9 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-(methylthio)- (9CI)
 (CA INDEX NAME)



RN 98567-17-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-(methylthio)-6-(2-propenyl)-

(9CI) (CA INDEX NAME)



L11 ANSWER 11 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:507713 CAPLUS
 DN 135:92807
 TI Preparation of imidazopyrimidine nucleoside analogs with anti-HIV activity
 IN Siddiqui, Arshad; Cimpoia, Alex; Preville, Patrice
 PA Biochem Pharma Inc., Can.
 SO PCT Int. Appl., 110 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001049700	A1	20010712	WO 2000-CA1587	20001228
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 2002061896	A1	20020523	US 2000-751488	20001228
PRAI	US 1999-173871P	P	19991230		
OS	MARPAT 135:92807				
AB	The present invention accordingly provides imidazopyrimidine nucleosides I wherein X is O, S, CH2; Y and Z are independently S, O, CF2, C=CH2, CHR6, R6 is OH, CN, halo, N3, NH2, SH, alkoxy, alkenyl, alkynyl, acyl, amine, sulfide, ; Y is CH, Z is CH, Y and Z are linked by double bond; R1 is H, alkyl, aryl, halogen; R2 is H, alkyl, acyl, aryl, heterocycle, acyloxycarbonyl, aryloxycarbonyl, halogen; R3 is H, alkyl, aryl, halogen; R4 is H, halogen; R5 is H, silylalkyl, acyl, phosphate; and a method for the treatment or prophylaxis of viral infections in mammals, including humans, comprising the step of administrating a therapeutically effective amt. of said compd. of formula I, salts or esters of said compd., pharmaceutical acceptable derivs. or pharmaceutically acceptable salts or esters thereof. Further embodiments include the use of said nucleosides in the prepn. of a medicament for the treatment of viral infections in mammals, a com. packages and pharmaceutical formulations comprising said nucleosides as a therapeutically effective agents against an HIV infection. Thus, 6-[(2S,5R)-5-hydroxymethyl oxolan-2-yl]-2-(4-fluorophenyl)-5,6-dihydro[1,3]-diazolo[1,2-C][1,3]diazin-5-one was prep'd. and tested for its antiviral activity (EC50 = 0.003-60 .mu.M) and cytotoxicity (CC50 > 100 .mu.M).				
IT	188251-80-1P 188251-82-3P 188251-83-4P 188251-85-6P 348597-29-5P 348597-30-8P 348597-31-9P 348597-32-0P 348597-33-1P 348597-34-2P 348597-35-3P 348597-39-7P 348597-43-3P 348597-44-4P 348597-45-5P 348597-46-6P 348597-50-2P 348597-51-3P 348597-52-4P 348597-55-7P 348597-56-8P 348597-58-0P 348597-59-1P 348597-60-4P 348597-63-7P 348597-64-8P 348597-69-3P 348597-70-6P 348597-72-8P 348597-73-9P 348597-74-0P 348597-77-3P 348598-39-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use);				

BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prep. of imidazopyrimidine nucleoside analogs with anti-HIV activity)

RN 188251-80-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2S,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 188251-82-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-83-4 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-85-6 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-29-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-30-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-phenyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-31-9 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(4-nitrophenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-32-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(4-methoxyphenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-33-1 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-(2-naphthalenyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-34-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-35-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-39-7 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2R,5R)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-43-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(hydroxymethyl)-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 348597-44-4 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 348597-45-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-(hydroxymethyl)-1,3-

oxathiolan-5-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 348597-46-6 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 348597-50-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-51-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-nitrophenyl)-6-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-52-4 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-nitrophenyl)-6-[(2R,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-55-7 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-56-8 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2S,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348597-58-0 CAPLUS
 CN L-Valine, [(4R)-4-[2-(4-fluorophenyl)-5-oxoimidazo[1,2-c]pyrimidin-6(5H)-yl]-1,3-dioxolan-2-yl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 348597-59-1 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 348597-60-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348597-63-7 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2S,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-64-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-nitrophenyl)-6-[(2S,5S)-tetrahydro-5-(hydroxymethyl)-2-furanyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-69-3 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2S,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-70-6 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-fluorophenyl)-6-[(2R,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-72-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-aminophenyl)-6-[(2S,5R)-tetrahydro-5-(hydroxymethyl)-2-furanyl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 348597-73-9 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(2-pyridinyl)-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 348597-74-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 348597-77-3 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4R)-2-(hydroxymethyl)-1,3-

dioxolan-4-yl]-2-(3-pyridinyl)-, mono(trifluoroacetate) (salt) (9CI) (CA INDEX NAME)

CM 1


CRN 348597-76-2
CMF C15 H14 N4 O4

Absolute stereochemistry.



CM 2


CRN 76-05-1
CMF C2 H F3 O2



RN 348598-39-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,4S)-2-(hydroxymethyl)-1,3-dioxolan-4-yl]-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 188251-79-8P 188251-87-8P 348597-28-4P
348597-37-5P 348597-38-6P 348597-40-0P

348597-41-1P 348597-42-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(prepn. of imidazopyrimidine nucleoside analogs with anti-HIV activity)

RN 188251-79-8 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-

(hydroxymethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 188251-87-8 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[(2S,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-5,6-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-28-4 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 5,6-dihydro-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-5-oxo-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-37-5 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[(2R,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-5,6-dihydro-5-oxo-, ethyl ester, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-38-6 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5R)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-(hydroxymethyl)-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 348597-40-0 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 5,6-dihydro-6-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-41-1 CAPLUS

CN Imidazo[1,2-c]pyrimidine-2-carboxylic acid, 6-[(2R,5S)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-5,6-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 348597-42-2 CAPLUS


CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[(2R,5S)-2-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,3-oxathiolan-5-yl]-2-(hydroxymethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT


L11 ANSWER 24 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1986:34281 CAPLUS
 DN 104:34281
 TI Ring-extended products from the reaction of epoxy carbonyl compounds and nucleic acid bases
 AU Nair, Vasu; Offerman, Rick J.
 CS Dep. Chem., Univ. Iowa, Iowa City, IA, 52242, USA
 SO Journal of Organic Chemistry (1985), 50(26), 5627-31
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 104:34281
 AB Purine and pyrimidine bases react with epoxy carbonyl compds. in aq. soln. to yield ring-extended adducts. These products include etheno-modified bases as well as adducts in which the modification involves the formation of an addnl. six-membered ring, e.g., reaction of cytidine with glycidaldehyde at pH 10 gave 41% base modified nucleoside I. The latter examples are among the first known cases of this type of modification of pyrimidine bases. Plausible mechanisms for the formation of these adducts are discussed.
 IT **90754-37-3P 99310-32-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 90754-37-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 99310-32-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 3-(hydroxymethyl)-2-methyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 25 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:542007 CAPLUS
 DN 103:142007
 TI Imidazo [1,2-c]pyrimidines and their salts their use as medicaments and compositions containing them
 IN Tully, Wilfred Roger
 PA Roussel-UCLAF , Fr.
 SO Eur. Pat. Appl., 20 pp.
 CODEN: EPXXDW
 DT Patent
 LA French
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 147312	A2	19850703	EP 1984-402661	19841219
	EP 147312	A3	19860430		
	EP 147312	B1	19890419		
	R: AT, BE, CH, DE, FR, IT, LI, LU, NL, SE				
	ZA 8409553	A	19860129	ZA 1984-9553	19841207
	US 4643999	A	19870217	US 1984-681948	19841214
	DK 8406054	A	19850623	DK 1984-6054	19841218
	AT 42292	E	19890515	AT 1984-402661	19841219
	AU 8436977	A1	19850704	AU 1984-36977	19841220
	AU 565745	B2	19870924		
	JP 60169479	A2	19850902	JP 1984-267623	19841220
	FI 8405102	A	19850623	FI 1984-5102	19841221
	FI 78099	B	19890228		
	FI 78099	C	19890612		
	GB 2151624	A1	19850724	GB 1984-32343	19841221
	GB 2151624	B2	19871111		
	HU 37431	A2	19851228	HU 1984-4792	19841221
	HU 192653	B	19870629		
	ES 538933	A1	19860316	ES 1984-538933	19841221
	CA 1233175	A1	19880223	CA 1984-470892	19841221
	ES 550003	A1	19861201	ES 1985-550003	19851216
PRAI	GB 1983-34210		19831222		
	EP 1984-402661		19841219		
OS	CASREACT	103:142007			
AB	Title compds. I (R = C6-12 aryl; R1 = H, alkyl, alkoxy, alkylthio, or R1R2 = O, or R2R3 form a bond; R3 = H, alkyl, alkenyl; R4 = alkoxy, alkylthio; R5 = H, alkyl), which were prep'd., exhibited anxiolytic activity. A mixt. of 2,6-dimethoxy-4-aminopyrimidine, BzCOCH2Br, Et2O, and THF was heated, the ppt. obtained was dissolved in EtOH, and the soln. was refluxed to give I (R = Ph, R4 = MeO, R1R2 = O, R3 = R5 = H).				
IT	98567-04-5P 98567-05-6P 98567-11-4P				
	98567-16-9P 98567-17-0P				
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)				
	(prepn. and anxiolytic activity of)				
RN	98567-04-5 CAPLUS				
CN	Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-methoxy- (9CI) (CA INDEX NAME)				




RN 98567-05-6 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-propyl- (9CI)
 (CA INDEX NAME)



RN 98567-11-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-(2-propenyl)- (9CI) (CA INDEX NAME)




RN 98567-16-9 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-6-ethyl-7-(methylthio)- (9CI)
 (CA INDEX NAME)



RN 98567-17-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-(methylthio)-6-(2-propenyl)-


(9CI) (CA INDEX NAME)



IT 98567-09-0P



RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 98567-09-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-benzoyl-7-methoxy-6-methyl- (9CI)
(CA INDEX NAME)


L11 ANSWER 26 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:437692 CAPLUS
 DN 103:37692
 TI Nucleoside annelating reagents: N-(tert-butoxycarbonyl)-2-bromoacetamide and 2-chloroketene diethyl acetal
 AU Leonard, Nelson J.; Cruickshank, Kenneth A.
 CS Sch. Chem. Sci., Univ. Illinois, Urbana, IL, 61801, USA
 SO Journal of Organic Chemistry (1985), 50(14), 2480-8
 CODEN: JOCEAH; ISSN: 0022-3263
 DT Journal
 LA English
 OS CASREACT 103:37692
 AB The title reagents undergo cyclocondensation reaction with tri-O-acetyladenosine to give imidazopyrimidines I ($R = 2,3,5$ -tri-O-acetyl-.beta.-D-ribofuranosyl; $R_1 = \text{NHCO}_2\text{CMe}_3$, OEt), resp., and with tri-O-acetylcytidine to give imidazopurines II. Some of the products exhibit useful fluorescence properties. Removal of the tert-butoxycarbonyl group with std. conditions gives the corresponding, somewhat unstable amino compds. which can be conveniently characterized as the corresponding N-acetyl derivs. The reagents introducing addnl. substitution on the etheno bridge, with enhanced fluorescence, also suggest the possibility of cross-linking functionalization.
 IT **96394-46-6P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and ester hydrolysis of)
 RN 96394-46-6 CAPLUS
 CN Acetamide, N-[5,6-dihydro-5-oxo-6-(2,3,5-tri-O-acetyl-.beta.-D-ribofuranosyl)imidazo[1,2-C]pyrimidin-2-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT **61671-71-4P**
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 61671-71-4 CAPLUS
 CN Acetamide, N-(5,6-dihydro-5-oxo-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 27 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1985:79272 CAPLUS
 DN 102:79272
 TI Comparative studies on reactions of adenosine and cytidine with chloroacetaldehyde, .alpha.-bromopropionaldehyde and chloroacetone. Synthesis of 1,N6-ethenoadenosine and 3,N4-ethenocytidine derivatives methylated at the etheno bridge
 AU Krzyzosiak, Włodzimierz J.; Biernat, Jacek; Ciesiolk, Jerzy; Gornicki, Piotr; Wiewiorowski, Maciej
 CS Inst. Bioorg. Chem., Pol. Acad. Sci., Poznan, 61704, Pol.
 SO Polish Journal of Chemistry (1983), 57(7-8-9), 779-87
 CODEN: PJCHDQ; ISSN: 0137-5083
 DT Journal
 LA English
 AB The rates of individual steps of the reactions of adenosine and cytidine with chloroacetaldehyde, .alpha.-bromopropionaldehyde and chloroacetone in water were compared. The nucleosides reacted with both .alpha.-haloaldehydes at comparable rates. The first reaction step, i.e. formation of the cyclic carbinolamine intermediate, was approx. 2 times faster in the .alpha.-bromopropionaldehyde reactions, whereas the second, i.e. dehydration, was 1.5 times more rapid in the case of chloroacetaldehyde. In the chloroacetone reactions the rate-detg. step was the slow initial addn. and no intermediates were obsd. The final products of .alpha.-bromopropionaldehyde and chloroacetone reactions were characterized by mass spectral UV and 1H NMR methods.
 IT 94837-41-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. and dehydration of)
 RN 94837-41-9 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(3H)-one, 2,6-dihydro-2-hydroxy-2-methyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 90754-37-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 90754-37-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 28 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1984:423869 CAPLUS
 DN 101:23869
 TI Comparative structural analysis of cytidine, ethenocytidine and their protonated salts. III. Proton, carbon-13 and nitrogen-15 NMR studies at natural isotope abundance
 AU Kozerski, Lech; Sierzputowska-Gracz, Hanna; Krzyzosiak, Włodzimierz; Bratek-Wiewiorowska, Maria; Jaskolski, Mariusz; Wiewiorowski, Maciej
 CS Inst. Bioorg. Chem., Pol. Acad. Sci., Poznan, 61-704, Pol.
 SO Nucleic Acids Research (1984), 12(4), 2205-23
 CODEN: NARHAD; ISSN: 0305-1048
 DT Journal
 LA English
 AB The ^1H , ^{13}C , ^{15}N NMR spectra of cytidine (I), ethenocytidine and their hydrochlorides were analyzed to compare structural differences obsd. in soln. with those existing in the cryst. state. The effects of etheno-bridging and protonation of the heteroarom. base on the intramol. stereochem., intermol. interactions and electronic structure of the whole mol. are discussed on the basis of the NMR studies in Me_2SO solns. Particular interest is devoted to the discussion of the conformation of the ribose ring, the presence of the intramol. C-5'-O...H-6-C hydrogen bond, unambiguous assignment of the site of protonation, the mechanism of the 5C-H D exchange in I.HCl, and the intermol. interactions in soln.
 IT 90754-37-3
 RL: PRP (Properties)
 (NMR of)
 RN 90754-37-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 30 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1983:558356 CAPLUS
 DN 99:158356
 TI Reactions of heterocyclic cations with N-containing nucleophiles. 13.
 Study of the reaction of 2,4,6-triarylpyrylium salts with hydrazines,
 semi- and thiosemicarbazides
 AU Zvezdina, E. A.; Zhdanova, M. P.; Anisimova, O. S.; Dorofeenko, G. N.
 CS Rostov. Gos. Univ., Rostov, 344006, USSR
 SO Khimiya Geterotsiklicheskikh Soedinenii (1983), (5), 695-701
 CODEN: KGSSAQ; ISSN: 0453-8234
 DT Journal
 LA Russian
 OS CASREACT 99:158356
 AB Recyclization reactions of perchlorates I ($R = H, p\text{-MeO}$) with $R_1\text{NH}_2$ ($R_1 = H, \text{Me}, \text{Ph}, \text{Bz}$) and PhCH:NNH_2 in DMF proceed differently than in EtOH.
 7-Hydroxy- and 7-thio derivs. of 2,3a,5-triphenyl-3H-pyrazolo[1.5-c]pyrimidine were obtained by treatment of triarylpyrylium salts with semi- and thiosemicarbazides. Thus, treatment of I ($R = H$) with PhCH:NNH_2 in DMF gave pyridinium perchlorate II; in EtOH diazepine salt III was formed. Treatment of I ($R = H$) with $\text{H}_2\text{NNHCXNH}_2$ ($X = \text{O}, \text{S}$) gave IV.
 IT 87483-67-8P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 87483-67-8 CAPLUS
 CN Pyrazolo[1,5-c]pyrimidin-7(3H)-one, 3a,6-dihydro-6-methyl-2,3a,5-triphenyl-
 (9CI) (CA INDEX NAME)




L11 ANSWER 32 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1978:418543 CAPLUS
 DN 89:18543
 TI A search for new fluorescent nucleotide derivatives: properties of 4'-substituted 2-phenylethenocytosines
 AU Shibaev, V. N.; Kost, A. A.; Kochetkov, N. K.; Razzhivin, A. P.; Ermolin, S. V.
 CS N. D. Zelinskii Inst. Org. Chem., Moscow, USSR
 SO Studia Biophysica (1978), 69(2), 91-102
 CODEN: STBIBN; ISSN: 0081-6337
 DT Journal
 LA English
 AB UV absorption and fluorescence of substituted 2-(4'-X-phenyl)-6-methylethenocytosines (where X = Me, MeO, Br, and NO₂ for I-IV, resp.) were investigated. The protonated species of the derivs. I-IV contg. substituents with (+M) effect were similar in UV spectra to 2-phenyl-6-methylethenocytosine (I) and showed intensive fluorescence. The emission max. shifted to long wavelengths with an increase of the (+M) effect of the substituent. Fluorescence of neutral species of the derivs. I-IV was less intense and emission max. were at shorter wavelengths in comparison with the protonated forms. The methoxy deriv. II seems to be the most promising as a fluorescent nucleic acid base analog in this series. For the nitro deriv. IV fluorescence of protonated species was not detected, whereas the neutral species showed weak long-wave length fluorescence in nonpolar solvents.
 IT 63803-95-2 63803-96-3 63803-97-4
 63803-98-5
 RL: PRP (Properties)
 (fluorescence and UV spectra of)
 RN 63803-95-2 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)


*Same as
#31.*



RN 63803-96-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-methoxyphenyl)-6-methyl- (9CI)
 (CA INDEX NAME)




RN 63803-97-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)



✓

RN 63803-98-5 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-(4-nitrophenyl)- (9CI) (CA INDEX NAME)



✓


IT 67147-87-9

RL: PRP (Properties)
(fluorescence of)


RN 67147-87-9 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-phenyl-6-.beta.-D-ribofuranosyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 33 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1978:116977 CAPLUS
 DN 88:116977
 TI Ethylene derivatives of cytosine as fluorescent probes in the study of D-glyceraldehyde-3-phosphate dehydrogenase
 AU Ermolin, S. V.; Kost, A. A.; Ivanov, M. V.; Nagradova, N. K.
 CS Mosk. Gos. Univ., Moscow, USSR
 SO Doklady Akademii Nauk SSSR (1978), 238(1), 245-8 [Biochem.]
 CODEN: DANKAS; ISSN: 0002-3264
 DT Journal
 LA Russian
 AB 2-Phenylethenocytosine derivs. substituted in the p-position of the benzene ring were methiodated to give the corresponding N1-methylated derivs. The binding of these compds. to yeast glyceraldehyde phosphate dehydrogenase (I) was studied. Binding of ethenocytosine derivs. to I resulted in quenching of their fluorescence, probably due to neutralization of the pos. charge on N1 by interaction with neg. charged groups in I. Scatchard plots indicated that there are 2 mols. ethenocytosine deriv. bound/mol. I and the dissocn. const. was 1.4 .times. 10-4 M. Since these mols. are hydrophobic in character, a relatively nonpolar region of I may be required for binding in addn. to neg. charged groups. The binding sites for ethenocytosine derivs. do not overlap with those for coenzyme or 1-anilino-8-naphthylsulfonate and N1-methylethenocytosine compds. are thus useful probes for investigating the conformational differences between sep. regions on the I mol.
 IT 65886-94-4 65886-95-5
 RL: BIOL (Biological study)
 (as glyceraldehyde phosphate dehydrogenase conformational probe)
 RN 65886-94-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidinium, 5,6-dihydro-1,6-dimethyl-2-(4-methylphenyl)-5-oxo-, iodide (9CI) (CA INDEX NAME)




● I⁻

RN 65886-95-5 CAPLUS
 CN Imidazo[1,2-c]pyrimidinium, 5,6-dihydro-2-(4-methoxyphenyl)-1,6-dimethyl-5-oxo-, iodide (9CI) (CA INDEX NAME)




● I⁻

L11 ANSWER 34 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:502261 CAPLUS
 DN 87:102261
 TI Fluorescent derivatives based on cytosine. Effect of substituents on optical properties of 2-phenylethenocytosines
 AU Kochetkov, N. K.; Shibaev, V. N.; Kost, A. A.; Razzhivin, A. P.; Ermolin, S. V.
 CS Inst. Org. Khim. im. Zelinskogo, Moscow, USSR
 SO Doklady Akademii Nauk SSSR (1977), 234(1), 227-30 [Biochem.]
 CODEN: DANKAS; ISSN: 0002-3264
 DT Journal
 LA Russian
 AB The title compds. I (R = Me, OMe, Br, NO₂), prep'd. in 23-52% yields by cyclocondensation of p-RC₆H₄COCH₂Br with 1-methylcytosine, showed little variation in their UV absorption detd. in 0.1NHCl, 0.1NKOH, and in CHCl₃.
 IT 63803-95-2P 63803-96-3P 63803-97-4P
 63803-98-5P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and fluorescence spectrum of)
 RN 63803-95-2 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-(4-methylphenyl)- (9CI) (CA INDEX NAME)




*Same #
#31*


RN 63803-96-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-methoxyphenyl)-6-methyl- (9CI) (CA INDEX NAME)



RN 63803-97-4 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-(4-bromophenyl)-6-methyl- (9CI) (CA INDEX NAME)





RN 63803-98-5 CAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-(4-nitrophenyl)- (9CI) (CA
INDEX NAME)




L11 ANSWER 35 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1977:106943 CAPLUS
 DN 86:106943
 TI Species responsible for the fluorescence of 3,N4-ethenocytidine
 AU Barrio, Jorge R.; Sattsangi, Prem D.; Gruber, Bruce A.; Dammann, Laurence
 G.; Leonard, Nelson J.
 CS Sch. Chem. Sci., Univ. Illinois, Urbana, IL, USA
 SO Journal of the American Chemical Society (1976), 98(23), 7408-13
 CODEN: JACSAT; ISSN: 0002-7863
 DT Journal
 LA English
 AB The fluorescence properties of 3,N4-ethenocytidine (.epsilon.-cytidine) (I), substituted derivs., and closely related 2-ring heterocycles were examd. The chloroacetaldehyde-modified cytidine is fluorescent only in its protonated form. The fluorescence emission max. is 340 nm and the pKa* is 4.0, very close to the value for the ground state. N-1-alkylation of I at the same position as protonation makes reversion to the nonfluorescent type of structure impossible, on changing the pH, and accordingly the fluorescence emission characteristics are preserved over a wide range of pH. The presence of the n.fwdarw..pi.* transition of the carbonyl group in I is responsible for the lack of fluorescence in neutral soln. Even I.HCl has a low fluorescence quantum yield (.PHI. < 0.01) and a short fluorescence lifetime (.tau. = 30 psec). Ring substitution produces a red shift of the .pi. .fwdarw. .pi.* transition, due to inductive or mesomeric effects and a clear improvement in the fluorescence emission characteristics; e.g., 2-acetylamo-5,6-dihydro-5-oxo-6-.beta.-D-ribosylylimidazo[1,2-c]pyrimidine, in its protonated form, shows .PHI. = 0.85 and .tau. = 4 ns. Imidazo[1,2-a]pyridine, a close model for I lacking the carbonyl group and accordingly the n .fwdarw. .pi.* transition, has a high fluorescence quantum yield and long lifetime in either neutral soln. or org. solvents. Both N-1-protonated and -alkylated imidazo[1,2-a]pyridines have emission maxima similar to those obsd. for I.HCl but higher quantum yields.
 IT 61671-71-4P
 RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and fluorescence spectra of)
 RN 61671-71-4 CAPLUS
 CN Acetamide, N-(5,6-dihydro-5-oxo-6-.beta.-D-ribosylylimidazo[1,2-c]pyrimidin-2-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 36 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1976:446992 CAPLUS
 DN 85:46992
 TI New fluorescent cytidine 5'-phosphate derivatives
 AU Kochetkov, N. K.; Shibaev, V. N.; Kost, A. A.; Razzhivin, A. P.; Borisov, A. Yu.
 CS N. D. Zelinskii Inst. Org. Chem., Moscow, USSR
 SO Nucleic Acids Research (1976), 3(5), 1341-9
 CODEN: NARHAD; ISSN: 0305-1048
 DT Journal
 LA English
 AB Interaction of cytidine 5'-phosphate with chloroacetone or p-tosyloxyacetone leads to 2-methyl-5,6-dihydro-5-oxo-6-(5-O-phospho-.beta.-D-ribofuranosyl)-2-imidazo[1,2-c]pyrimidine (I, R = Me) whereas analogous reaction with phenacyl bromide gave I (R = Ph). I showed significant uv absorption at long wavelength where common nucleotides and proteins exhibited no absorption. I are highly fluorescent when heterocyclic ring is protonated.
 IT 59968-40-0P 60003-82-9P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 59968-40-0 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-6-(5-O-phosphono-.beta.-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 60003-82-9 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-phenyl-6-(5-O-phosphono-.beta.-D-ribofuranosyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L11 ANSWER 37 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1976:105526 CAPLUS
 DN 84:105526
 TI Preparation of substituted imidazo[1,2-c]pyrimidines from
 N'-methylcytosine
 AU Kochetkova, N. K.; Kost, A. N.; Shibaev, V. N.; Sagitullin, R. S.; Kost,
 A. A.; Zav'yalov, Yu. V.
 CS Inst. Org. Khim. im. Zelinskogo, Moscow, USSR
 SO Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1975), (12), 2766-70
 CODEN: IASKA6; ISSN: 0002-3353
 DT Journal
 LA Russian
 OS CASREACT 84:105526
 AB Imidazopyrimidines (I, R = Me, Ph, R1 = H; R = H, R1 = Me, H) were
 obtained in 23-31% yields by cyclocondensation of 1-methylcytosine with
 RCOCH₂Br by boiling 12 hr in dry MeOH.
 IT 57491-47-1P 57491-49-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 57491-47-1 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2,6-dimethyl- (9CI) (CA INDEX NAME)




Same #31
as

RN 57491-49-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-phenyl- (9CI) (CA INDEX NAME)




L11 ANSWER 38 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1976:3973 CAPLUS
 DN 84:3973
 TI Fluorescent properties of some cytosine derivatives modified with
 .alpha.-halocarbonyl compounds
 AU Razhivin, A. P.; Kost, A. A.; Shibaev, V. N.
 CS Lab. Bio-Org. Chem., M. V. Lomonosov Moscow State Univ., Moscow, USSR
 SO Studia Biophysica (1975), 51(1), 29-34
 CODEN: STBIBN; ISSN: 0081-6337
 DT Journal
 LA English
 AB The uv and fluorescence spectra of I (R, R1 = H, H; Me, H; Me; Ph, H)
 were reported. The fluorescence quantum yields increased as the pH of the
 medium decreased. The abs. quantum yield for I (R = Ph, R1 = H) in acidic
 media was 0.60. I were prep'd. by reaction of N1-methylcytosine with
 .alpha.-halocarbonyl compds.
 IT 57491-47-1 57491-49-3
 RL: PRP (Properties)
 (fluorescence and uv spectra of)
 RN 57491-47-1 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2,6-dimethyl- (9CI) (CA INDEX NAME)



#31
Same as

RN 57491-49-3 CAPLUS
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-methyl-2-phenyl- (9CI) (CA INDEX NAME)



L11 ANSWER 39 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1975:443668 CAPLUS

DN 83:43668

TI Reactions with organophosphorus compounds. XXXVI. Structural transformations on nucleotides, nucleosides, and nucleoside bases using .beta.-acylvinylphosphonium salts

AU Ivancsics, Christine; Zbiral, Erich

CS Org.-Chem. Inst., Univ. Wien, Vienna, Austria

SO Monatshefte fuer Chemie (1975), 106(2), 417-28

CODEN: MOCMB7; ISSN: 0026-9247

DT Journal

LA Russian

AB Treatment of CMP with AcCH:CHP+Ph₃ Br- (I) gave the etheno deriv. [II, R₁ = R₃ = H, R₂ = P(O)(ONa)₂, R₄ = P+Ph₃ Br-] whereas guanine gave III (R = P+Ph₃Br-) (IV) and V. Degradn. of IV with di-Et malonate anion in Me₂SO at 90.degree. for 48 hr gave 44.8% III [R = CH(CO₂Et)₂]. Wittig reaction of II (R₁ = R₂ = SiMe₃, R₃ = H, R₄ = P+Ph₃Br-) with PhCHO gave II (R₁ = R₂ = SiMe₃, R₃R₄ = CHPh).

IT 55857-97-1P



RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. and Wittig reaction of)

RN 55857-97-1 CAPLUS

CN Phosphonium, [[5,6-dihydro-2-methyl-5-oxo-6-[2,3,5-tris-O-(trimethylsilyl)-.beta.-D-ribofuranosyl]imidazo[1,2-c]pyrimidin-3-yl]methyl]triphenyl-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br-

IT 55857-96-0P 55857-98-2P 55917-73-2P

RL: SPN (Synthetic preparation); PREP (Preparation)


(prepn. of)

RN 55857-96-0 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 2-methyl-3-(2-phenylethenyl)-6-[2,3,5-tris-O-(trimethylsilyl)-.beta.-D-ribofuranosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry unknown.



RN 55857-98-2 CAPLUS

CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 3-ethenyl-2-methyl-6-[2,3,5-tris-O-(trimethylsilyl).beta.-D-ribosyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 55917-73-2 CAPLUS

CN Phosphonium, [[5,6-dihydro-2-methyl-5-oxo-6-(5-O-phosphono-.beta.-D-ribofuranosyl)imidazo[1,2-c]pyrimidin-3-ylmethyl]triphenyl-, bromide, disodium salt (9CI) (CA INDEX NAME)

Absolute stereochemistry.

● Br⁻

●2 Na


IT 35536-42-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(reaction of, with bis(trimethylsilyl)acetamide)

RN 35536-42-6 CAPIUS

CN Phosphonium, [(5,6-dihydro-2-methyl-5-oxo-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-3-yl)methyl]triphenyl-, bromide (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



L11 ANSWER 40 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1973:160044 CAPLUS

DN 78:160044

TI Reactions with phosphororganic compounds. XXXIII. Structural transformations on nucleosides and nucleoside bases by (.beta.-acylvinyl)triphenylphosphonium salts

AU Hugl, Erika; Schulz, Gerhard; Zbiral, Erich

CS Org.-Chem. Inst., Univ. Wien, Vienna, Austria

SO Justus Liebigs Annalen der Chemie (1973), (2), 278-89
CODEN: JLACBF; ISSN: 0075-4617

DT Journal

LA German

AB The structures of the condensed heterocyclic systems I [R = Me (II) or H (III)], IV [R = H, R1 = Me (V) or Ph], and VI formed by reaction of the corresponding nucleosides or nucleoside bases with Ph₃P+CH:CHCOMe Br⁻ (VII) were elucidated, II by the nuclear Overhauser effect and III and V by Hofmann-like degrdn. The reactive intermediate formed from III led to the formation of the ester VIII (R = H) by addn. of the malonate carbanion. Similarly, the derivs. IX [R₂ = CN, CH(COMe)CO₂Et, or CH(CO₂Et)₂] were formed from IV. Wittig reaction of II with BzH gave the cis and trans isomers of X (R = Me). Similarly, the compd. XI obtained from 2-aminopyridine with VII reacted with BzH to give the styryl deriv. XII.


IT 35536-42-6P 35536-44-8P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 35536-42-6 CAPLUS

CN Phosphonium, [(5,6-dihydro-2-methyl-5-oxo-6-.beta.-D-ribosylfuranosylimidazo[1,2-c]pyrimidin-3-yl)methyl]triphenyl-, bromide (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

● Br⁻

RN 35536-44-8 CAPLUS

CN Phosphonium, [(5,6-dihydro-2-methyl-5-oxo-6-(2,3,5-tri-O-acetyl-.beta.-D-ribosyl)imidazo[1,2-c]pyrimidin-3-yl)methyl]triphenyl-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

L11 ANSWER 41 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1972:488530 CAPLUS

DN 77:88530

TI Protozoacidal 2-alkylpyrazolo[1,5-c]pyrimidines

IN Kranz, Eckart; Bock, Marianne

PA Farbenfabriken Bayer A.-G.

SO Ger. Offen., 21 pp.

CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2058501	A	19720531	DE 1970-2058501	19701127
	NL 7116162	A	19720530	NL 1971-16162	19711124
	US 3810894	A	19740514	US 1971-201987	19711124
	AT 310736	B	19731010	AT 1971-10166	19711125
	BE 775893	A1	19720526	BE 1971-110966	19711126
	FR 2115446	A5	19720707	FR 1971-42515	19711126
	FR 2115446	B1	19750801		
	DD 95235	C	19730122	DD 1971-159193	19711126
	GB 1333311	A	19731010	GB 1971-55026	19711126
	CH 560701	A	19750415	CH 1971-17263	19711126
	CA 988085	A1	19760427	CA 1971-128663	19711126
	HU 163827	P	19731128	HU 1971-BA2671	19711127

PRAI DE 1970-2058501 19701127


AB Twenty-one title compds. (I, R = Me, Ph, iso-Pr, R1 = H, Me, X = O, S, NH; II, R = Me, Ph, Et, Pr, iso-Pr, R1 = Me, Et, R2 = NH2, NHMe, SMe; III, R = Me, Ph, n = 1, 2; IV, and V), protozoacides and intermediates for the synthesis of plant-protecting agents, were prepd. by reaction of beta-triketones with hydrazine derivs. Thus, H2NCONHNH2.HCl was heated 6 hr with (MeCOCH2)2CO and aq. Na2CO3 at 100.degree. to give 60.2% II (R = R1 = Me, R2 = NH2).

IT 35834-00-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 35834-00-5 CAPLUS

CN Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2,5,6-trimethyl- (9CI) (CA INDEX NAME)



L11 ANSWER 42 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1972:488523 CAPLUS

DN 77:88523

TI Protozoacidal 2-alkylpyrazolo[1,5-c]pyrimidines

IN Kranz, Eckart; Bock, Marianne

PA Farbenfabriken Bayer A.-G.

SO Ger. Offen., 18 pp.


CODEN: GWXXBX

DT Patent

LA German

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 2058500	A	19720531	DE 1970-2058500	19701127
	NL 7116161	A	19720530	NL 1971-16161	19711124
	AT 310737	B	19731010	AT 1971-10167	19711125
	DD 95009	C	19730112	DD 1971-159188	19711126
	HU 163826	P	19731128	HU 1971-BA2670	19711127
PRAI	DE 1970-2058500		19701127		
AB	Eighteen title compds. (I, R = Me, iso-Pr, Ph, R1 = H, Me, X = O, S, NH; II, R = Me, Ph, Et, Pr, iso-Pr, R1 = Me, Et, R2 = NH2, NHMe, SMe; III, n = 1, 2), and 2,5-dimethylpyrazolo [1 ,5 :3,4] pyrimido [1,2-.alpha.] benzimidazole,, protozoacides, were prep'd. by reaction of 3,6-disubstituted 4-hydroxy-2-pyrones with hydrazines. Thus, H2NCSNHNH2 was heated 8 hr with dehydracetic acid in concd. HCl at 110.degree. to give 33.6% I (R = Me, R1 = H, X = S).				
IT	35834-00-5P				
	RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of)				
RN	35834-00-5	CAPLUS			
CN	Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2,5,6-trimethyl- (9CI) (CA INDEX NAME)				

*Same**at # 41*

L11 ANSWER 43 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1972:113172 CAPLUS

DN 76:113172

TI Reactions with organophosphorus compounds. XXXI. Reaction of adenine, cytosine, and guanine derivatives with B-acylvinylphosphonium salts. Potentially useful principle for modification of nucleic acids

AU Zbiral, E.; Hugl, Erika

CS Org.-Chem. Inst., Univ. Wien, Vienna, Austria

SO Tetrahedron Letters (1972), (5), 439-44

CODEN: TELEAY; ISSN: 0040-4039

DT Journal

LA German

AB Cytidine condensed with Ph₃PCH:CHAc to give the imidazopyrimidine I (R = Ph₃PCH₂, R₁ = Me, or vice versa), which gave I (R = R₁ = Me) and Ph₃PO on treatment with alkali. Cytidine, adenine, adenosine, and guanosine also underwent the reaction. Yields were 57-70%. The imidazopyridine II (R = Ph₃PCH₂) or its isomer, prep'd. similarly, underwent Wittig reaction to give II (R = PhCH:CH) or its isomer.

IT 35536-42-6P 35536-43-7P 35536-44-8P


35536-45-9P

RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of)

RN 35536-42-6 CAPLUS

CN Phosphonium, [(5,6-dihydro-2-methyl-5-oxo-6-.beta.-D-ribosylfuranosylimidazo[1,2-c]pyrimidin-3-yl)methyl]triphenyl-, bromide (9CI)
(CA INDEX NAME)


Absolute stereochemistry.

● Br⁻

RN 35536-43-7 CAPLUS

CN Phosphonium, [(5,6-dihydro-3-methyl-5-oxo-6-(2,3,5-tri-O-acetyl-.beta.-D-ribosyl)imidazo[1,2-c]pyrimidin-2-yl)methyl]triphenyl-, bromide
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br^-

RN 35536-44-8 CAPLUS

CN Phosphonium, [[5,6-dihydro-2-methyl-5-oxo-6-(2,3,5-tri-O-acetyl-.beta.-D-ribofuranosyl)imidazo[1,2-c]pyrimidin-3-ylmethyl]triphenyl-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Br^-

RN 35536-45-9 CAPLUS


CN Phosphonium, [(5,6-dihydro-3-methyl-5-oxo-6-.beta.-D-ribofuranosylimidazo[1,2-c]pyrimidin-2-yl)methyl]triphenyl-, bromide (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Br^-

L11 ANSWER 44 OF 44 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1972:113161 CAPLUS
 DN 76:113161
 TI Pyrazolo[1,5-c]pyrimidine - a new heterocyclic system
 AU Kranz, Eckart; Kurz, Juergen; Donner, Wolfgang
 CS Wiss. Lab., Farbenfabr. Bayer A.-G., Wuppertal-Elberfeld, Fed. Rep. Ger.
 SO Chemische Berichte (1972), 105(2), 388-405
 CODEN: CHBEAM; ISSN: 0009-2940
 DT Journal
 LA German
 OS CASREACT 76:113161
 AB Reaction of dehydracetic acid with H₂NNHCXNH₂ (X = S, O, or NH) gave 7-thioxo-6,7-dihydro- (I, X = S), 7-oxo-6,7-dihydro- (I, X = O), and 7-amino-2,5-dimethylpyrazolo[1,5-c]pyrimidine (II). Theoretically I and II can exist in 3 tautomeric forms. In order to prove in which form they exist, alkylation expts. were performed. The structures of the N-, O-, or S-alkyl derivs. obtained were detd. by NMR and mass spectra. The structures of I and II were detd. by comparing the uv spectra of the alkylated products with those of the starting materials. Proton signals of products prep'd. were identified by using the spin decoupling method. Bond orders and charge densities of 2,5-dimethylpyrazolo[1,5-c]pyrimidine were calcd. by the CNDO method.
 IT 35834-00-5P 35834-01-6P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of)
 RN 35834-00-5 CAPLUS
 CN Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2,5,6-trimethyl- (9CI) (CA INDEX NAME)




Same as #41

RN 35834-01-6 CAPLUS
 CN Pyrazolo[1,5-c]pyrimidin-7(6H)-one, 2,5,6-trimethyl-, compd. with sodium iodide (NaI) (2:1) (9CI) (CA INDEX NAME)

CM 1

CRN 35834-00-5
 CMF C9 H11 N3 O



10/634,225

CM 2

CRN 7681-82-5
CMF I Na

I--Na

=> d his

(FILE 'HOME' ENTERED AT 16:22:13 ON 24 FEB 2004)

FILE 'REGISTRY' ENTERED AT 16:22:22 ON 24 FEB 2004

L1 STRUCTURE UPLOADED
L2 50 S L1 SSS SAM
L3 2657 S L1 SSS FUL
L4 STRUCTURE UPLOADED
L5 50 S L4 SSS SAM SUB=L3
L6 2133 S L4 SSS FUL SUB=L3
L7 STRUCTURE UPLOADED
L8 12 S L7 SSS SAM SUB=L3
L9 411 S L7 SSS FUL SUB=L3
L10 117 S L3 NOT L6 NOT L9

FILE 'CAPLUS' ENTERED AT 16:31:12 ON 24 FEB 2004


L11 44 S L10

FILE 'CAOLD' ENTERED AT 16:32:56 ON 24 FEB 2004

=> s l10
L12 1 L10


=> d l12 bib,hitstr

L12 ANSWER 1 OF 1 CAOLD COPYRIGHT 2004 ACS on STN
 AN CA61:4345d CAOLD
 TI pyrimidines - (III) rearrangement in the syntheses of imidazo- or
 pyrimidol[1,2-c]pyrimidines, (IV) interconversion of N4-methylcytosine and
 3-methylcytosine
 AU Ueda, Tohru; Fox, J. J.
 IT 93738-70-6 96117-01-0
 RN 93738-70-6 CAOLD
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 3-hydroxy-2,6-dimethyl-, acetate (7CI)
 (CA INDEX NAME)




RN 96117-01-0 CAOLD
 CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 3-hydroxy-2,6-dimethyl-, acetate,
 acetate (salt) (7CI) (CA INDEX NAME)

CM 1

CRN 93738-70-6
CMF C10 H11 N3 O3

CM 2

CRN 64-19-7
CMF C2 H4 O2

10/634,225

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	3.15	448.56
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-30.49

STN INTERNATIONAL LOGOFF AT 16:33:25 ON 24 FEB 2004